These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37786976)

  • 1. Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series.
    Lapucci C; Boccia VD; Sirito T; Cellerino M; Mikulska M; Sticchi L; Inglese M
    Mult Scler; 2023 Oct; 29(11-12):1514-1517. PubMed ID: 37786976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis.
    Mathew T; Kamath V; John SK; Netravathi M; Iyer RB; Raghavendra S; Kumar S; Neeharika ML; Gupta S; Murgod U; Shivakumar R; Annadure RK; Ichaporia N; Rohatgi A; Nair SS; Yareeda S; Anand B; Singh P; Renukaradhya U; Arulselvan V; Reddy YM; Surya N; Sarma GRK; Nadig R; Deepalam S; Sharath Kumar GG; Satishchandra P; Singhal BS; Parry G
    Mult Scler Relat Disord; 2022 Oct; 66():104059. PubMed ID: 35908446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy.
    Kinner M; Prehn C; Schneider R; Schroeder C; Kolb E; Gold R; Hoepner R; Chan A
    Eur J Neurol; 2021 Mar; 28(3):921-927. PubMed ID: 33085811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
    Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab.
    Mulero P; Auger C; Parolin L; Fonseca E; Requena M; Rio J; Tintoré M; Rovira A; Montalban X
    Mult Scler; 2018 Mar; 24(3):358-360. PubMed ID: 28643544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the safety of live attenuated varicella-zoster virus vaccination in patients with relapse-remitting multiple sclerosis treated with natalizumab: A case series and review of the literature.
    Paybast S; Sahraian MA; Nahayati MA; Habibi MA; Shahmohammadi S; Navardi S
    Mult Scler Relat Disord; 2023 Sep; 77():104793. PubMed ID: 37413854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance.
    Kågström S; Fält A; Berglund A; Piehl F; Olsson T; Lycke J
    Mult Scler Relat Disord; 2021 May; 50():102842. PubMed ID: 33610957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.
    Kohlmann R; Salmen A; Chan A; Knabbe C; Diekmann J; Brockmeyer N; Skaletz-Rorowski A; Michalik C; Gold R; Überla K
    Mult Scler; 2015 Dec; 21(14):1823-32. PubMed ID: 25828755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report.
    Miranda Acuña JA; Weinstock-Guttman B
    Mult Scler Relat Disord; 2016 Sep; 9():54-5. PubMed ID: 27645344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE).
    Smoot K; Marginean H; Gervasi-Follmar T; Chen C; Repovic P; Cohan S
    Mult Scler; 2023 Jul; 29(8):956-966. PubMed ID: 37317841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
    Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
    JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk.
    Boziki MK; Karapanayotides T; Papadopoulos G; Lagoudaki R; Melo P; Bakirtzis C; Nikolaidis I; Gounari E; Tsavdaridou V; Skoura L; Afrantou T; Tatsi T; Grigoriadou E; Polyzoidou E; Mandoras N; Giantzi V; Kalogera-Fountzila A; Ioannidis P; Parissis D; Pelidou SH; Zoidou S; Grigoriadis N
    Neurol Res; 2020 Mar; 42(3):209-221. PubMed ID: 32048570
    [No Abstract]   [Full Text] [Related]  

  • 14. Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging.
    Hodel J; Outteryck O; Dubron C; Dutouquet B; Benadjaoud MA; Duhin E; Verclytte S; Zins M; Luciani A; Rahmouni A; Pruvo JP; Vermersch P; Leclerc X
    Radiology; 2016 Mar; 278(3):863-72. PubMed ID: 26436861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
    Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E
    J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned.
    Major EO; Yousry TA; Clifford DB
    Lancet Neurol; 2018 May; 17(5):467-480. PubMed ID: 29656742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.
    Mowry EM; McArthur JC
    Neurology; 2017 Mar; 88(12):1110-1111. PubMed ID: 28228562
    [No Abstract]   [Full Text] [Related]  

  • 18. Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.
    Fissolo N; Pignolet B; Matute-Blanch C; Triviño JC; Miró B; Mota M; Perez-Hoyos S; Sanchez A; Vermersch P; Ruet A; de Sèze J; Labauge P; Vukusic S; Papeix C; Almoyna L; Tourbah A; Clavelou P; Moreau T; Pelletier J; Lebrun-Frenay C; Montalban X; Brassat D; Comabella M;
    Ann Neurol; 2017 Aug; 82(2):186-195. PubMed ID: 28681388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab.
    Sgarlata E; Chisari CG; D'Amico E; Millefiorini E; Patti F
    CNS Drugs; 2020 May; 34(5):535-543. PubMed ID: 32221861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?
    Scarpazza C; Prosperini L; Mancinelli CR; De Rossi N; Lugaresi A; Capobianco M; Moiola L; Naldi P; Imberti L; Gerevini S; Capra R
    J Neurol Sci; 2017 Jul; 378():233-237. PubMed ID: 28566170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.